

C1
Concl immunologically reactive with any epitope presented by either IL-B30 alone or p40 alone.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned, "Version with markings to show changes made."

REMARKS

New Claims 51-62 are pending in the application. Claim 51 is amended to correct a simple typographical error. The Examiner requested a clean version and marked-up version of amended Claim 51. This amendment supplies the clean version and marked-up version of amended Claim 51.

Applicants believe that no new matter is added by way of amendment.

Respectfully submitted,

Date: February 14, 2002

By: Sheela Mohan-Peterson
Sheela Mohan-Peterson
Attorney for Applicants
Reg. No. 41,201

DNAX Research Institute
901 California Avenue
Palo Alto, California, 94304-1104
Tel. No. (650) 496-6400
Fax No.: (650) 496-1200

VERSION WITH MARKINGS TO SHOW CHANGES MADE

51. (Amended Once) A binding compound comprising an antigen binding site from an antibody, which specifically binds to a mammalian IL-B30/p40 complex, said complex comprising an IL-B30 subunit (SEQ ID NO:2 or 4) and a p40 subunit of [complex comprising an IL-B30 subunit (SEQ ID NO:2 or 4) and a p40 subunit of] human or murine origin, wherein said antibody immunologically reacts with an epitope presented by the IL-B30/p40 complex, but is not substantially immunologically reactive with any epitope presented by either IL-B30 alone or p40 alone.